Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.47 |
| ▸ | KMO | O15229 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 4/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | GRN | P28799 | 1/20 | 0.37 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3656925 | 0.91 | APP (0.48) | APPAKR1C3AKR1C2KMOCNR2 | |
| SCHEMBL3659879 | 0.91 | APP (0.58) | APPAKR1C3AKR1C2KMOCNR2 | |
| SCHEMBL1202763 | 0.89 | APP (0.58) | APPAKR1C3AKR1C2KMOCNR2 | |
| SCHEMBL15494192 | 0.87 | APP (0.57) | APPKMOCNR2PSEN1PSEN2 | |
| SCHEMBL3655298 | 0.87 | APP (0.74) | APPAKR1C3AKR1C2KMOCNR2 | |
| SCHEMBL3714452 | 0.86 | APP (0.58) | APPAKR1C3AKR1C2KMOCNR2 | |
| SCHEMBL3715858 | 0.86 | APP (0.75) | APPAKR1C3AKR1C2KMOCNR2 | |
| SCHEMBL1203137 | 0.85 | APP (0.58) | APPAKR1C3AKR1C2KMOCNR2 | |
| SCHEMBL15111391 | 0.85 | APP (0.55) | APPAKR1C3AKR1C2KMOCNR2 | |
| SCHEMBL3655231 | 0.82 | APP (0.49) | APPKMOCNR2GRM2FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234954-B1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS INC (US) | 2015-02-18 | — | — | EP | disclosed |
| EP-2234954-B1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS INC (US) | 2015-02-18 | — | — | EP | disclosed |
| US-20140364641-A1 | Tetrasubstituted Benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364641-A1 | Tetrasubstituted Benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364641-A1 | Tetrasubstituted Benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-8664249-B2 | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664249-B2 | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664249-B2 | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| WO-2013106328-A1 | TETRASUBSTITUTED BENZENES FOR TREATMENT OF EARLY ONSET ALZHEIMER'S DISEASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | WO | disclosed |
| US-20130165486-A1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120295981-A1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-8217064-B2 | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217064-B2 | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8217064-B2 | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| EP-2234954-A1 | TETRASUBSTITUTED BENZENES | Envivo Pharmaceuticals, Inc. (US) | 2010-10-06 | — | — | EP | disclosed |
| US-20090299072-A1 | Tetrasubstituted Benzenes | EN VIVO PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090299072-A1 | Tetrasubstituted Benzenes | EN VIVO PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090299072-A1 | Tetrasubstituted Benzenes | EN VIVO PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| WO-2009086277-A1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086277-A1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364641-A1 | Tetrasubstituted Benzenes | BACE1, BACE2, PSEN1 | APP 5/4885AKR1C3 4151/4885AKR1C2 3649/4885 |
| US-20090299072-A1 | Tetrasubstituted Benzenes | BACE1, BACE2, PSEN1 | APP 5/4885AKR1C3 4151/4885AKR1C2 3649/4885 |
| US-20120295981-A1 | TETRASUBSTITUTED BENZENES | BACE1, BACE2, PSEN1 | APP 5/4885AKR1C3 4151/4885AKR1C2 3649/4885 |
| US-20130165486-A1 | TETRASUBSTITUTED BENZENES | BACE1, BACE2, PSEN1 | APP 5/4885AKR1C3 4151/4885AKR1C2 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.